Do analysts recommend CASI or BCLI?

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher possible upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CASI or BCLI more profitable?

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% Brainstorm Cell Therapeutics N/A N/A -519.50%

Do analysts prefer CASI or BON?

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CASI or BON?

Bon Natural Life has lower revenue, but higher earnings than CASI Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CASI Pharmaceuticals $26.85M 0.10 -$39.26M -$3.01 N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is CASI or BON more profitable?

Bon Natural Life has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% Bon Natural Life N/A N/A N/A

Do analysts prefer GELS or CASI?

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, GELS or CASI?

Gelteq has higher earnings, but lower revenue than CASI Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 65.62 -$4.30M N/A N/A CASI Pharmaceuticals $26.85M 0.10 -$39.26M -$3.01 N/A

Is GELS or CASI more profitable?

Gelteq has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A CASI Pharmaceuticals -183.93% N/A -131.54%

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 06/29/2026

Compare

CASI vs. BCLI, BON, APRE, GELS, and RVPH

Should you buy CASI Pharmaceuticals stock or one of its competitors? MarketBeat compares CASI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CASI Pharmaceuticals include Brainstorm Cell Therapeutics (BCLI), Bon Natural Life (BON), Aprea Therapeutics (APRE), Gelteq (GELS), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry.

How does CASI Pharmaceuticals compare to Brainstorm Cell Therapeutics?

CASI Pharmaceuticals (NASDAQ:CASI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher possible upside, equities analysts plainly believe CASI Pharmaceuticals is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for CASI Pharmaceuticals. Brainstorm Cell Therapeutics' average media sentiment score of 0.75 beat CASI Pharmaceuticals' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Brainstorm Cell Therapeutics	Positive

Summary

CASI Pharmaceuticals beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Bon Natural Life?

CASI Pharmaceuticals (NASDAQ:CASI) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Bon Natural Life has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Bon Natural Life	N/A	N/A	N/A

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bon Natural Life had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Bon Natural Life and 0 mentions for CASI Pharmaceuticals. Bon Natural Life's average media sentiment score of 1.91 beat CASI Pharmaceuticals' score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Bon Natural Life	Very Positive

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Bon Natural Life has lower revenue, but higher earnings than CASI Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Summary

Bon Natural Life beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Aprea Therapeutics has higher earnings, but lower revenue than CASI Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Aprea Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CASI Pharmaceuticals has a net margin of -183.93% compared to Aprea Therapeutics' net margin of -4,405.59%. CASI Pharmaceuticals' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

In the previous week, Aprea Therapeutics had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for Aprea Therapeutics and 0 mentions for CASI Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 1.29 beat CASI Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Positive
CASI Pharmaceuticals	Neutral

Aprea Therapeutics currently has a consensus price target of $4.07, indicating a potential upside of 408.33%. CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aprea Therapeutics beats CASI Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Gelteq?

Gelteq (NASDAQ:GELS) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Gelteq has higher earnings, but lower revenue than CASI Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	65.62	-$4.30M	N/A	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Gelteq has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Gelteq has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Gelteq had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Gelteq and 0 mentions for CASI Pharmaceuticals. Gelteq's average media sentiment score of 0.43 beat CASI Pharmaceuticals' score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Neutral
CASI Pharmaceuticals	Neutral

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

CASI Pharmaceuticals beats Gelteq on 7 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Reviva Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Reviva Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat CASI Pharmaceuticals' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Reviva Pharmaceuticals	Neutral

Reviva Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

CASI Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 10,284.22%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Reviva Pharmaceuticals beats CASI Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55M	$3.05B	$6.80B	$12.48B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.07	19.69	25.72	24.65
Price / Sales	0.10	356.93	545.41	102.66
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	1.73	4.24	10.94	6.52
Net Income	-$39.26M	$64.45M	$3.57B	$336.61M
7 Day Performance	N/A	2.81%	2.21%	1.24%
1 Month Performance	N/A	3.36%	0.55%	0.28%
1 Year Performance	-82.42%	34.26%	36.44%	30.62%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
BCLI Brainstorm Cell Therapeutics	0.6098 of 5 stars	$0.91 +1.1%	N/A	-15.1%	$10.04M	N/A	N/A	40	Gap Up
BON Bon Natural Life	1.2255 of 5 stars	$1.21 flat	N/A	-4.0%	$9.84M	$18.67M	N/A	100	Gap Up
APRE Aprea Therapeutics	4.0335 of 5 stars	$0.83 +4.3%	$4.07 +391.1%	-51.1%	$9.83M	$290K	N/A	7	News Coverage Short Interest Decrease
GELS Gelteq	0.6263 of 5 stars	$0.73 -16.0%	N/A	-64.7%	$9.33M	$110K	N/A	N/A	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BCLI, BON, APRE, GELS, and RVPH

How does CASI Pharmaceuticals compare to Brainstorm Cell Therapeutics?

Summary

How does CASI Pharmaceuticals compare to Bon Natural Life?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Summary

How does CASI Pharmaceuticals compare to Gelteq?

Summary

How does CASI Pharmaceuticals compare to Reviva Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. BCLI, BON, APRE, GELS, and RVPH

How does CASI Pharmaceuticals compare to Brainstorm Cell Therapeutics?

Do insiders & institutionals believe in CASI or BCLI?

Do analysts recommend CASI or BCLI?

Is CASI or BCLI more profitable?

Which has preferable earnings & valuation, CASI or BCLI?

Which has more risk & volatility, CASI or BCLI?

Does the media prefer CASI or BCLI?

Summary

How does CASI Pharmaceuticals compare to Bon Natural Life?

Is CASI or BON more profitable?

Do insiders and institutionals hold more shares of CASI or BON?

Do analysts prefer CASI or BON?

Does the media refer more to CASI or BON?

Which has more volatility and risk, CASI or BON?

Which has preferable valuation and earnings, CASI or BON?

Summary

How does CASI Pharmaceuticals compare to Aprea Therapeutics?

Which has higher valuation & earnings, APRE or CASI?

Which has more risk & volatility, APRE or CASI?

Do institutionals & insiders believe in APRE or CASI?

Is APRE or CASI more profitable?

Does the media favor APRE or CASI?

Do analysts prefer APRE or CASI?

Summary

How does CASI Pharmaceuticals compare to Gelteq?

Which has higher valuation & earnings, GELS or CASI?

Which has more risk & volatility, GELS or CASI?

Is GELS or CASI more profitable?

Do analysts prefer GELS or CASI?

Does the media favor GELS or CASI?

Do institutionals & insiders believe in GELS or CASI?

Summary

How does CASI Pharmaceuticals compare to Reviva Pharmaceuticals?

Do insiders & institutionals hold more shares of CASI or RVPH?

Which has more volatility & risk, CASI or RVPH?

Is CASI or RVPH more profitable?

Does the media refer more to CASI or RVPH?

Which has higher valuation and earnings, CASI or RVPH?

Do analysts rate CASI or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools